IPP Bureau
Bayer starts Phase III trial in non-small cell lung cancer
By IPP Bureau - August 30, 2024
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
Bayer awards incubator opportunity to Genvor
By IPP Bureau - August 30, 2024
Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies
Lupin receives USFDA approval for Brimonidine Tartrate Ophthalmic Solution, 0.1%
By IPP Bureau - August 28, 2024
Brimonidine Tartrate Ophthalmic Solution, 0.1% is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure
Aptar Closures introduces new lightweight 2? Disc Top Lite Closure for beauty and personal care
By IPP Bureau - August 28, 2024
The low-profile, 2” Disc Top Lite closure offers lighter weight combined with premium customization options
Zydus receives USFDA final approval for Amantadine ER capsules 68.5 mg
By IPP Bureau - August 28, 2024
Also received tentative approval for 137 mg
Royal Sense launches multiple products in pharmaceutical category
By IPP Bureau - August 28, 2024
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
Mastek and Onyx Health partner to accelerate healthcare data interoperability
By IPP Bureau - August 28, 2024
The partnership will provide health plans with an out-of-the-box compliance solution for CMS-9115 and CMS-0057 rules
India's bioeconomy to reach US $300 billion by 2030: Dr. Jitendra Singh
By IPP Bureau - August 27, 2024
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
EC approves Ordspono for the treatment of relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma
By IPP Bureau - August 27, 2024
Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission
Merck receives EC approval for Winrevair for treatment of PAH
By IPP Bureau - August 27, 2024
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
Mangalam Drugs & Organics awarded US$ 274,800 grant by MMV
By IPP Bureau - August 27, 2024
The grant is designated for the research and development of Pyronaridine
Shilpa Medicare receives USFDA approval for Bortezomib injection
By IPP Bureau - August 27, 2024
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH
By IPP Bureau - August 27, 2024
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Bristol Myers Squibb to present data across cardiovascular portfolio at ECS 2024
By IPP Bureau - August 27, 2024
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
Pfizer launches digital platform ‘PfizerForAll’
By IPP Bureau - August 27, 2024
PfizerForAll works within the existing healthcare system and through a growing network of partners to simplify access via established channels and to close gaps in care
